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A series of 2-(pyridinyl)pyrimidines were identified as potent 
GPR40 antagonists.  Despite significant challenges related to 10 
improving the combination of potency and lipophilicity 
within the series, the compounds were optimised to identify a 
suitable in vivo probe compound, which was confirmed to 
exhibit pharmacology consistent with GPR40 antagonism. 
GPR40 (FFAR1) is a family A GPCR which is highly and 15 
selectively expressed on the human insulin secreting beta-cells of 
the pancreas.1  When activated, the receptor is coupled to the Gq 
signal transduction mechanism and mediates an increase in 
intracellular calcium and the secretion of insulin.  Insulin 
secretion only occurs when glucose concentrations are high and 20 
thus GPR40 agonists have been considered good candidates for 
treatment of type 2 diabetes without risk of hypoglycaemia.  This 
hypothesis has been vindicated in clinical trials with Fasiglifam, 
TAK-875 (Fig. 1), Takeda’s GPR40 agonist,2 although the recent 
failure of the compound in Phase III trials has given rise to safety 25 
concerns based on hepatotoxicity.3  The naturally occurring 
ligands for GPR40 are thought to be saturated fatty acids which 
have long been considered to have a chronic  lipotoxic effect on 
the beta-cell.4  Thus an alternative hypothesis would be that if the 
lipotoxic effects of saturated fatty acids were mediated by GPR40 30 
then an antagonist approach, whilst being contraindicated acutely 
(lowering of insulin secretion), would in the long run be a 
beneficial therapy.  Data from GPR40 deleted mice and 
transgenic over expression of GPR40 have yielded controversial 
results.  Studies have shown a benefit of GPR40 knockout on the 35 
metabolic defects of high fat fed mice5,6 and a detrimental effect 
of beta-cell specific over expression of GPR40.  However, both 
of these claims have been countered.7-11 
It has been shown recently that human islets cultured long term in 
the presence of a GPR40 antagonist (ANT203, Fig. 1) showed a 40 
number of beneficial effects, including inhibition of the 
detrimental effects of palmitate on glucose stimulated insulin 
secretion and insulin content, 12 although perhaps contrary results 
have also been described.13-15  ANT203 has some undesirable 
structural properties containing a non-druglike hydrazone group 45 
as well as very high logD7.4 resulting in low solubility and very 
poor bioavailability. Hence, the programme to identify more 
drug-like GPR40 antagonist compounds described herein was 
initiated, with the goal of testing the GPR40 lipotoxicity 
hypothesis in vivo.  A number of groups have also disclosed 50 
GPR40 antagonists in the literature.16-19 
TAK-875                ANT-203
GPR40 pIC50 6.6 (antagonist)
LogD7.4 4.3
Solubility <0.3 µM  
Fig. 1 Structures of TAK-875 and ANT203 
In order to identify antagonists of GPR40, a high throughput 
screen of the AstraZeneca compound collection was carried out, 55 
screening in HEK cells stably transfected with GPR40 stimulated 
with elaidic acid and measuring the secondary messenger IP1 by 
time resolved fluorescence as an endpoint.  Active compounds 
were selected for IC50 determination and confirmation of activity 
using calcium flux as an alternative end point.  This exercise 60 
identified pyrimidine 1 (Fig. 2) as a moderately potent (pIC50 6.2) 





LogD 2.7  
Fig. 2 Initial hit and removal of morpholine 
Compound 1 was originally synthesised as part of a programme 65 
to identify inhibitors of the human target of rapamycin.20  As a 
consequence, it carried some weak activity against lipid kinases 
such as phosphatidyl inositol-3-kinase (pIC50 4.2 and 4.8 for the α 
and β subtypes respectively). Lipid kinases of this type are known 
to make a critical hydrogen bonding interaction between a 70 
backbone NH in the protein and the morpholine oxygen.21  Initial 
exploration of analogues of 1 revealed that the morpholine could 
be replaced with a methyl group (2) with retained GPR40 
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antagonist activity and equivalent lipophilicity (pIC50 6.1, logD7.4 
2.7) and thus removing concerns about lipid kinase activity 
during optimisation. 
The structure activity relationships of 2 were explored with a 
view to improving potency and, ideally, reducing lipophilicity 5 
[improving lipophilic ligand efficiency (LLE, pIC50-logD7.4)].
22  
Exploration of the pyridine substituent at the pyrimidine 2-
position of 2 suggested that the 2-pyridyl was optimal.  For 
instance other pyridine isomers had reduced potency (data not 
shown). 10 
A systematic exploration of substituent effects on the pendant 
phenyl group was then carried out (Table 1).  This revealed a 
strong link between potency and lipophilicity in this region.  
Potency could be increased by incorporation of a chloro- 
substituent with a concomitant increase in logD7.4.  2-substitution 15 
(3) appeared better marginally better than 3- or 4- substitution (4 
and 5) having a pIC50 of 6.5 and a logD7.4 of 3.4 and, hence, a 
slight increase in LLE relative to phenyl derivative 2 (0.4 units).  
Incorporation of polar substituents methoxy- (6, 7 and 8), cyano- 
(9, 10 and 11), acetamido- (12, 13 and 14) and methanesulfonyl 20 
(15, 16 and 17) led to reduced potency in all cases.  Slight 
benefits in potency could be achieved with fluoro-substitution, 
most notably again at the 2-position [pIC50 6.4, 6.1, 6.2 for 2-, 3- 
and 4- isomers (18, 19 and 20) respectively] without significant 
increases in lipophilicity (logD7.4 2.9, 3.1 and 3.0).  As a result, 25 
the 2-fluorophenyl derivative 18 showed an improvement in LLE 
of 0.8 log units relative to phenyl 2 (3.5 vs. 2.7).  Additional 
exploration of this group by replacement with aromatic or 
aliphatic heterocycles showed diminished potency and no 
improvement in LLE (see ESI). 30 
Table 1 Exploration of substitution of the phenyl ring 
R
 
R pIC50 logD7.4 pIC50- logD7.4 
Ph (2) 6.1 3.4 2.7 
2-chlorophenyl (3) 6.5 3.4 3.1 
3-chlorophenyl (4) 6.4 3.7 2.7 
4-chlorophenyl (5) 6.6 3.7 2.9 
2-methoxyphenyl (6) 5.7 2.5 3.2 
3-methoxyphenyl (7) 5.7 2.9 2.8 
4-methoxyphenyl (8) 5.1 2.8 2.3 
2-cyanophenyl (9) 5.0 2.7 2.3 
3-cyanophenyl (10) 5.6 2.7 2.9 
4-cyanophenyl (11) 4.5 2.6 1.9 
2-acetamidophenyl (12) <4.4 1.6 - 
3-acetamidophenyl (13) <4.4 2.1 - 
4-acetamidophenyl (14) <4.4 1.9 - 
2-methanesulfonyl (15) <4.4 1.5 - 
3-methanesulfonyl (16) <4.4 1.7 - 
4-methanesulfonyl (17) <4.4 1.5 - 
2-fluorophenyl (18) 6.4 2.9 3.5 
3-fluorophenyl (19) 6.1 3.1 3.0 
4-fluorophenyl (20) 6.2 3.0 3.2 
 
Given the relationship between potency and lipophilicity 
observed in this region, it appeared that the best strategy to 
optimise LLE was to exploit the apparent benefit of fluorination.  35 
Accordingly, combinations of di- and tri-fluorination patterns 
were explored (Table 2).  All combinations of difluorination (21, 
22 and 23) appeared to be similar in potency to the 2-fluoro 
derivative 18 with slight increases in lipophilicity (reduced LLE).  
For the trifluoro derivatives, the 2,3,4-isomer 24 appeared to 40 
possess the best balance of potency and lipophilicity (pIC50 6.6, 
logD7.4 3.3) with other combinations (25–29) showing slightly 
reduced potency, increased lipophilicity or both.  Accordingly, 
2,3,4-trifluoro derivative 24 was identified as the optimal 
fluorination pattern.  This represented an increase in potency 45 
from the initial phenyl derivative 2 of 0.5 log units with no 
change in lipophilicity.  Whilst these changes are small, they are 
meaningful; the potency values for phenyl 2, 2-fluorophenyl 18 
and 2,3,4-trifluorophenyl 24 derivatives were shown to be 
statistically significantly different to each other (see ESI). 50 
 
Table 2 Effect of multiple phenyl ring fluorine substitutions 
R
 
R pIC50 logD7.4 pIC50- logD7.4 
2,3-difluorophenyl (21) 6.4 3.2 3.2 
2,4-difluorophenyl (22) 6.4 3.1 3.3 
3,4-difluorophenyl (23) 6.3 3.2 3.1 
2,3,4-trifluorophenyl (24) 6.6 3.3 3.3 
2,3,5-trifluorophenyl (25) 6.3 3.4 2.9 
2,3,6-trifluorophenyl (26) 5.8 3.1 2.7 
2,4,5-trifluorophenyl (27) 6.4 3.2 3.2 
2,4,6-trifluorophenyl (28) 5.9 3.2 2.7 
3,4,5-trifluorophenyl (29) 6.4 3.4 3.0 
 
At the same time, replacement of the pyrimidine 4-methyl 
substituent was explored. Initial analogues were prepared with a 55 
3-fluorophenyl as the ether substituent (Table 3).  This revealed 
that oxygen and nitrogen links (the latter precedented from the 
initial hit) were tolerated although both the methoxy- (30) and 
dimethylamino- (32) derivatives showed slightly reduced potency 
with increased lipophilicity and hence reduced LLE (2.3 and 2.2) 60 
respectively relative to 3.0 for methyl derivative 19).  Potency 
could be increased on both the ether and amine linked series with 
larger and more lipophilic alkyl substituents such as ethyl (31 and 
33) and isopropyl (34). 
Table 3 Initial replacements of the pyrimidine 4-methyl substituent 65 
R
 
R pIC50 logD7.4 pIC50-logD7.4 
-Me (19) 6.1 3.1 3.0 
-OMe (30) 5.9 3.6 2.3 
-OEt (31) 6.6 4.1 2.5 
-NMe2 (32) 5.8 3.6 2.2 
-NHEt (33) 6.2 3.9 2.3 
NHiPr (34) 7.0 4.3 2.7 
 
Subsequently, these observations were further developed in the 
optimised 2,3,4-trifluorophenyl ether series (Table 4).  In the 
nitrogen linked series, it was discovered that a dimethylazetidine 
substituent (35) gave a significant potency  increase (pIC50 7.6 70 
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relative to 6.6 for methyl 24) in line with the lipophilicity 
increase (constant LLE).  Incorporation of polar substituents such 
as hydroxyl (36), oxetanyl (37), and methanesulfonylmethyl (38) 
at the azetidine-3-position all served to reduce the logD but at the 
cost of potency resulting in LLE values that were all less than that 5 
of the methyl derivative 24.  The best balance was observed with 
the 3-cyano-3-methylazetidine derivative 39 (pIC50 6.8, logD7.4 
3.3). 
In the oxygen linked series, it was observed that further potency 
benefits could be obtained with lipophilic substituents.  The 10 
2,2,2-trifluoroethyl derivative 40 was the most potent compound 
(pIC50 8.1) although, again, with immeasurably high logD7.4.  
The cyclobutylmethylether 41 showed similar potency with lower 
logD7.4 and with more scope to introduce polar substituents to 
reduce the lipophilicity.  The oxetanyl derivative 42 showed 15 
reduced potency and LLE relative to the cyclobutyl. 
Incorporation of a methyl group at the oxetane 3-position (43) 
increased potency significantly with an increase in LLE despite 
the increase in logD7.4 and suggested that further substitution 
may be possible at this position.  Changing the methyl group for 20 
methoxy (44) served to reduce lipophilicity and potency whereas 
a cyanomethyl substituent (45) retained potency relative to the 
unsubstituted oxetane with a reduction in logD and thus slightly 
increased LLE (3.1 relative to 2.8 for the unsubstituted oxetane).  
The best balance (highest LLE) within this subseries was 25 
displayed by the 3-fluorooxetane derivative 46 (pIC50 7.2, logD7.4 
4.0). 
Table 4 Further changes to the pyrimidine 4-methyl substituent 
 
R pIC50 logD7.4 pIC50- logD7.4 
-Me (24) 6.6 3.3 3.3 
(35) 
7.6 4.3 3.3 
(36) 
5.5 2.8 2.7 
(37) 
6.3 3.3 3.0 
(38) 
5.2 2.9 2.3 
(39) 
6.8 3.3 3.5 
(40) 
8.1 >4.9 - 
(41) 
7.9 4.5 3.4 
(42) 
6.5 3.7 2.8 
(43) 
7.1 4.0 3.1 
(44) 
6.3 3.5 2.8 
(45) 
6.4 3.3 3.1 
(46) 
7.2 4.0 3.2 
 
Whilst these examples illustrate that optimisation of LLE in this 30 
series is challenging, compounds 39 and 46 show the best balance 
of potency and lipophilicity and show improved potency and LLE 
relative to starting point 2 (0.7 and 1.1 log increases in potency 
and 0.8 and 0.5 unit increases in LLE for 39 and 49 respectively 
compared to 2, see also Fig. 5). 35 
Subsequently, a crystal structure of GPR40 bound to the allosteric 
agonist TAK-875 has been obtained.23  This shows that the ligand 
binds in an unusual allosteric pocket, formed between 
transmembrane helices 3, 4 and 5.  Analysis of the crystal 
structure revealed no other pocket large enough to accommodate 40 
compounds from our series.  It was therefore hypothesised that 
the compounds reported here bind in the same site as TAK-875, 
but in such a way as to cause antagonism rather than agonism.  
The structure is appropriate for antagonist binding as it has 
crystallised in the inactive form.     45 
In order to better understand ligand binding to GPR40 the crystal 
structure was subjected to an energetic analysis using the 3D-
RISM method24 implemented in the MOE software package.25  
The analysis identified predicted locations of water molecules 
within the binding site and their associated stability as free-50 
energy of binding (Fig. 3a).  Two predicted water sites were 
identified within the pocket, close to the carboxylic acid of the 
ligand, which were not, in reality, occupied in the crystal 
structure.  These sites can also be interpreted as locations of 
potential ligand-protein interactions and these were selected as 55 
pharmacophore points (any ligand atom) for docking.  An 
induced-fit docking protocol was used where, after initial pose 
generation, protein side-chains within 6Å of the ligand were 
optimised along with the ligand.  Compound 39 was docked 
using this method and it was observed that both pharmacophore 60 
sites were occupied with polar groups from the ligand (Fig. 3b).  
The pyridine group was observed to form a hydrogen bond to 
Arg183, though the geometry was sub-optimal.  The cyano group 
made no hydrogen bonds, but also contacted Arg183.  
Furthermore, the lipophilic interactions of the phenyl group in 65 
TAK-875 were replicated nicely by the phenyl of 39.  In order to 
accommodate the pyridine ring, Leu171 rotated and opened up a 
large sub-pocket towards transmembrane helix 2.  This marked 
the most significant departure from the binding mode of TAK-
875 and so it could be proposed that occupying this pocket is the 70 
reason for the observed antagonism of these compounds, rather 
than the agonism of TAK-875. 
a)  
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b)  
Fig. 3 (a) 3D-RISM solvent analysis of GPR40 in complex with TAK-
875 (PDB=4PHU23).  Spheres indicate predicted water molecule sites 
where the numeric label indicates the ∆G of binding (kcal/mol): green 
(negative ∆G) is stable, red (positive ∆G) is unstable.  (b) GPR40 5 
structure with compound 39 bound.  Leu171 and Arg183 have both 
moved from their original positions (also drawn) during the induced-fit 
docking protocol 
The 3D model also agrees with the observation that much of the 
SAR is lipophilicity driven.  The binding site shows very little 10 
hydrophilic character (blue/red coloured surface in Fig. 2) with 
the exception of potential interactions with Arg183 and nearby 
residues at one end of the binding site.  Binding affinity 
throughout the rest of the molecule is largely driven by non-polar 
contacts. 15 
Despite their non-ideal lipophilicity,26 compounds 24, 39 and 46 
all showed reasonable ADMET properties (Table 5) although 39 
and 46 had poorer solubility and some hERG activity.  The 
compounds showed moderate intrinsic clearance in rat 
hepatocytes although values were higher in human microsomes.  20 
Consistent with the rat in vitro data, all three compounds had 
moderate rat clearance and 24 and 39 showed good 
bioavailability and fraction absorbed in rat pharmacokinetic 
studies, resulting in sufficient oral exposure to be suitable as in 
vivo probes.  In addition, 39 had comparable activity against the 25 
rat and mouse GPR40 isoforms and had no measurable activity 
against the related fatty acid receptor GPR43 (FFAR2) and a 
relatively benign secondary pharmacology profile [only 1 target 
(pig Na+/K+ ATPase)out of 144 tested showed potency greater 
than 1 µM, for further details see ESI] making it a suitable in vivo 30 
probe. 




(24) (39) (46) 
GPR40 pIC50 hu / rat 6.6 / 6.7 6.8 / 7.2 7.2 / 7.5 
logD7.4 3.3 3.3 4.0 
Solubility / µM 22 2.9 2.9 
%free (rat / hu) 6.3 / 3.0 5.6 / 4.8 1.7 / 1.5 
hERG pIC50 < 4.5 5.0 5.2 
Clint (rat hep / hu mics) / 
mLmin-1106 
17 / 57 26 / 52 72 / 56 
Rat Cl (Clu) / mLmin
-1kg-1 24 (380) 30 (540) 19 (1100) 
Rat Vss / Lkg
-1 2.3 3.0 1.4 
Rat F (Fabs) %  39 (59) 32 (56) 12 (16) 
 
To confirm that compound 39 effects GPR40 antagonism in vivo, 
it was tested in a β3-agonist challenge (lipolysis) model in the 35 
insulin resistant Zucker fa/fa rats.7  Male Zucker rats (n=8/group) 
were dosed with either vehicle (PVP/SDS 5 mg/kg, p.o.) or 39 at 
80 mg/kg with or without β3-agonist pre-treatment 30 minutes 
prior to dosing.  4 hours post dosing, plasma samples were 
collected and non-esterified fatty acids (NEFA) and insulin levels 40 
were measured using ELISA assays.  The data show that, in the 
absence of the β3-agonist challenge, plasma NEFA concentration 
remained at a basal level (Fig. 4a) and that the GPR40 antagonist 
did not alter insulin secretion compared with vehicle (Fig. 4b).  
However, in the presence of the β3-agonist the plasma NEFA 45 
levels of vehicle treated animals increased by 6-fold which 
produced a concomitant fatty acid driven insulin secretion 3.5-
fold above the vehicle treated animals without a β3-challenge.  
The GPR40 antagonist significantly inhibited NEFA driven 
insulin secretion by ~70% (P<0.01), such that it was only 1.7-fold 50 
above the non β3-challenge state.  These data suggest that GPR40 
antagonists can reduce fatty acid stimulated insulin secretion, 
which may be therapeutically beneficial for hyperinsulinaemic 
and insulin resistant states where fatty acid potentiation of 
glucose stimulated insulin secretion (GSIS) is a major source of 55 
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b)  
Fig. 4 Effect of 39 on β3-agonist stimulated NEFA (a) and insulin (b) 
levels in Zucker fa/fa rats. Vehicle non- β3-agonist (green), 39 without β3 
agonist (red), vehicle with β3-agonist (blue), 39 with β3-agonist (black). 
Conclusions 5 
The structure activity relationships described here highlight the 
lipophilic nature of the GPR40 binding pocket and the challenges 
that compound optimisation in such a situation presents.  
Nevertheless, incremental improvements were possible by 
systematic structural exploration, most notably by exploiting the 10 
isolipophilic changes of multiple fluorine substitutions on the 
phenyl ring.  This work allowed the identification of compounds 
suitable as in vivo probes, most notably compound 39, although 
the scope for further optimisation of this series is questionable.  
Further studies describing the pharmacological evaluation of 39, 15 
assessing the consequences of GPR40 antagonism in vivo, will be 
the subject of further publications. 
The use of LLE to assess the effect of structural modifications on 
potency in the context of changes in lipophilicity was useful.  The 
use of composite parameters such as LLE has recently been the 20 
subject of controversy27 with justified points concerning the 
thermodynamic and mathematical basis for LLE (potency 
offsetting) being raised.28  In this study, the use of LLE is 
justifiable from this perspective, since the compounds show a 
very clear relationship between pIC50 and logD7.4 values and the 25 
line of best fit in the corresponding scatter plot has a gradient of 
unity (Fig. 5).  It might be hypothesised that this is what would 
be expected for a series in which affinity is driven by lipophilic 
interactions. 
 30 
Fig. 5 LLE plot for the series.  Red line shows the line of best fit 
(pIC50=2.6+1.1logD7.4, r
2=0.65), red dotted lines show the 95% 
confidence in the fit, green line is the line of slope = 1. Key compounds 
are highlighted 2 (red), 24 (green), 39 (blue). 
Data obtained from a β3-agonist challenge carried out using the 35 
GPR40 knockout mouse demonstrated that potentiation of GSIS 
by GPR40 contributes to ~50% of all insulin secretion under 
hyperlipidaemic conditions.  A reduction in insulin levels from 
35 ng/mL to 18ng/mL during the β3– agonist challenge suggests 
that the antagonist 39 was able to completely inhibit the NEFA 40 
driven potentiation of GSIS pharmacologically, in line with the 
maximum contribution this mechanism can make to GSIS 
implied by the knockout mouse data.8  Further studies on the 
pharmacology of these compounds will be reported in due course. 
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synthesis of 39, tests for statistical differences in potency values, further 50 
details of the molecular modelling and the secondary pharmacology 
profile of 39. See DOI: 10.1039/b000000x/ 
 
1 A. D. Mancini, V. Poitout, Trends Endocrin. Met. 2013, 24, 398. 
2 C. F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, 55 
B. Xie, E. Leifke, Lancet 2012, 379, 1403. 
3 A. D. Mancini, V. Poitout, Diabetes, Obes. Metab., doi: 
10.1111/dom.12442 
4 M. Prentki, E. Joly, W. El-Assaad, R. Roduit,  Diabetes 2002, 51, 
S405. 60 
5 P. Steneberg, N. Rubins, R. Bartoov-Shifman, M. D. Walker, H. 
Edlund, Cell Metab. 2005, 1, 245. 
6 R. Brownlie, R. M. Mayers, J. A. Pierce, A. E. Marley, D. M. Smith, 
Biochem. Soc. Trans. 2008, 36, 950. 
7 H. Lan, L. M. Hoos, L. Liu, G. Tetzloff, W. Hu, S. J. Abbondanzo, 65 
G. Vassileva, E. L. Gustafson, J. A. Hedrick, H. R. Davis, Diabetes 
2008, 57, 2999. 
8 M. G. Latour, T. Alquier, E. Oseid, C. Tremblay, T. L. Jetton, J. Luo, 
D. C. Lin, V. Poitout, Diabetes 2007, 56, 1087. 
9 K. Nagasumi, R. Esaki, K. Iwachidow, Y. Yasuhara, K. Ogi, H. 70 
Tanaka, M. Nakata, T. Yano, K. Shimakawa, S. Taketomi, K. 
Takeuchi, H. Odaka, Y. Kaisho, Diabetes 2009, 58, 1067. 
10 C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, C. Zhou, 
S. Lin, G. Salituro, P. Mainke, R. Mosley, T. E. Akiyama, M. 
Einstein, S. Kumar, J. P. Berger, S. G. Mills, N. A. Thornberry, L. 75 






































































































 6  |  Journal Name, [year], [vol], 00–00 This journal is © The Royal Society of Chemistry [year] 
11 M. Kebede, T. Alquier, M. G. Latour, M. Semache, C. Tremblay, V. 
Poitout, Diabetes, 2008, 57, 2432.  
12 H. Kristinsson, D. M. Smith, P. Bergsten, E. Sargsyan, 
Endocrinology, 2013, 154, 4078. 
13 R. Wagner, G. Kaiser, F. Gerst, E. Christiansen, M. E. Due-Hansen, 5 
M. Grundmann, F. Machicao, A. Peter, E. Kostenis, T. Ulven, A. 
Fritsche, H.-U. Häring, S. Ullrich, Diabetes, 2013, 62, 2106. 
14 P. Wu, L. Yang, X. Shen, Biochem. Biophys. Res. Commun. 2010, 
403, 36. 
15 Y. Zhang, M. Xu, S. Zhang , L. Yan, C. Yang, W. Lu, Y. Li, H. 10 
Cheng, J. Mol. Endocrinol. 2007, 38, 651. 
16 Y. Zhao, J. Liao, Heterocycles, 2011, 83, 1145; X. Zhang, G. Yan, Y. 
Li, W. Zhu, H. Wang, Biomed. Pharmacol. J. 2010, 64, 647. 
17 H. Hu, L. Y. He, Z. Gong, N. Li, Y. N. Lu, Q. W. Zhai, H. Liu, H. L. 
Jiang, W. L. Zhu, H. Y. Wang, Biochem. Biophys. Res. Commun. 15 
2009, 390, 557. 
18 P. S. Humphries, J. W. Benbow, P. D. Bonin, D. Boyer, S. D. Doran, 
R. K. Frisbie, D. W. Piotrowski, G. Balan, B. M. Bechle, E. L. Conn, 
K. J. Dirico, R. M. Oliver, W. C. Soeller, J. A. Southers, X. Yang. 
Bioorg. Med. Chem. Lett. 2009, 19, 2400. 20 
19 C. P. Briscoe, A. J. Peat, S. C. McKeown, D. F. Corbett, A. S. Goetz, 
T. R. Littleton, D. C. McCoy, T. P. Kenakin, J. L. Andrews, C. 
Ammala, J. A. Fornwald, D. M. Ignar, S. Jenkinson, Br. J. 
Pharmacol. 2006, 148, 619. 
20 K. G. Pike, M. R. V. Finlay, S. M. Fillery, A. P. Dishington, PCT Int. 25 
Appl. WO2007080382. 
21 M. R. V. Finlay, D. Buttar, S. E. Critchlow, A. P. Dishington, S. M. 
Fillery, E. Fisher, S. C. Glossop, M. A. Graham, T. Johnson, G. M. 
Lamont, S. Mutton, P. Perkins, K. G. Pike, A. M. Slater, Bioorg. 
Med. Chem. Lett. 2012, 22, 4163. 30 
22 A. L. Hopkins, G. M. Keserü, P. D. Leeson, D. C. Rees, C. H. 
Reynolds, Nat. Rev. Drug Discov. 2014, 13, 105. 
23 A. Srivastava, J. Yano, Y. Hirozane, G. Kefala, F. Gruswitz, G. Snell, 
W. Lane, A. Ivetac, K. Aertgeerts, J. Nguyen, A. Jennings, K. Okada, 
Nature 2014, 513, 124. 35 
24 D. Chandler, H. C. Anderson, J. Chem. Phys. 1972, 57, 1930. 
25 http://www.chemcomp.com/MOE-
Molecular_Operating_Environment.htm 
26 M. J. Waring, Expert Opin. Drug Discov. 2010, 5, 235. 
27 M. D. Schultz, Bioorg. Med. Chem. Lett. 2013, 23, 5980. 40 
28 P. W. Kenny, A. Leitão, C. A. Montanari, J. Comput. Aided Mol. 
Des. 2014, 28, 699. 
 
Page 6 of 6MedChemComm
M
ed
C
he
m
C
om
m
A
cc
ep
te
d
M
an
us
cr
ip
t
Pu
bl
ish
ed
 o
n 
08
 A
pr
il 
20
15
. D
ow
nl
oa
de
d 
by
 K
ee
le
 U
ni
ve
rs
ity
 o
n 
16
/0
4/
20
15
 1
6:
07
:0
5.
 
View Article Online
DOI: 10.1039/C5MD00037H
